Disopyramide Phosphate
9 NDCs across 5 manufacturers|7 Generic,2 Brand
Disopyramide Phosphate is used to treat atrial fibrillation, atrial flutter and ventricular premature complexes, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Feb 22, 1985. FDA's Orange Book lists 6 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $4 million on Disopyramide Phosphate across 12,000 claims for 2,802 beneficiaries.
Disopyramide Phosphate is available as 9 NDCs from 5 manufacturers (7 generic, 2 brand), with NADAC prices from $0.80 to $4.91 per EA — the most expensive product costs about 6.1× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
9
7G / 2B
Manufacturers
5
competing in market
Price Spread
$0.80 – $4.91
per EA
7d Activity
avg -1.9% WoW · of 9 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Pfizer Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Antiarrhythmic class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
5 manufacturers producing DISOPYRAMIDE PHOSPHATE(2 pricing outliers)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
NORPACE CR 150 MG CAPSULE | $4.9062 per EA | — |
NORPACE CR 100 MG CAPSULE | $4.1412 per EA | — |
DISOPYRAMIDE 150 MG CAPSULE | $1.5318 per EA | +2.08% |
DISOPYRAMIDE 150 MG CAPSULE | $1.5318 per EA | +2.08% |
DISOPYRAMIDE 150 MG CAPSULE | $1.5318 per EA | +2.08% |
DISOPYRAMIDE 100 MG CAPSULE | $0.8437 per EA | — |
DISOPYRAMIDE 100 MG CAPSULE | $0.8005 per EA | -5.89% |
DISOPYRAMIDE 100 MG CAPSULE | $0.8005 per EA | -5.89% |
DISOPYRAMIDE 100 MG CAPSULE | $0.8005 per EA | -5.89% |
Frequently Asked Questions
What is Disopyramide Phosphate used to treat?
Disopyramide Phosphate is used to treat atrial fibrillation, atrial flutter and ventricular premature complexes, per the National Library of Medicine's MED-RT classification.
When did Disopyramide Phosphate become available as a generic?
FDA approved the first generic Disopyramide Phosphate (ANDA) on Feb 22, 1985. The Orange Book currently lists 6 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Disopyramide Phosphate?
In 2024, Medicare Part D spent $4 million on Disopyramide Phosphate across 12,000 claims for 2,802 beneficiaries.
How many Disopyramide Phosphate products are on the market?
The Disopyramide Phosphate drug market contains 9 NDCs from 5 manufacturers — 7 generic and 2 brand products.
What is the price range for Disopyramide Phosphate?
NADAC reference prices for Disopyramide Phosphate range from $0.8005 to $4.9062 per EA — the most expensive product costs about 6.1× the cheapest.
Is generic Disopyramide Phosphate cheaper than brand?
The average generic NADAC for Disopyramide Phosphate is $1.1201 per EA, versus $4.5237 for brand-labeled products — brand versions average about 4.0× the generic price.
Which manufacturers make Disopyramide Phosphate?
5 manufacturers list Disopyramide Phosphate in NADAC. Ranked by number of NDCs, the largest are Pfizer Inc. (2), Mylan Pharmaceuticals Inc. (2), Dr. Reddy's Laboratories Inc. (2), Teva Pharmaceuticals USA Inc. (2), Mayne Pharma (1).
How has the price of Disopyramide Phosphate changed recently?
Over the past 7 days, 3 Disopyramide Phosphate NDCs rose and 3 fell, with a market-wide average change of -1.9%.